Director/PDMR Shareholding

RNS Number : 6124C

Circassia Pharmaceuticals Plc

18 March 2014

 



For immediate release

Circassia Pharmaceuticals plc

Directors' Dealing

Oxford, UK - 18 March 2014: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR), a clinical-stage specialty biopharmaceutical company, announces that it has received notification from Steven Harris, Chief Executive Officer of the Company, and Charles Swingland, Non-Executive Director of the Company, that they have undertaken certain transfers of their Ordinary Shares which constitute a dealing in the Company's shares for the purposes of the Disclosure Rules and Transparency Rules.

As disclosed in the Company's prospectus dated 13 March 2014 in relation to the recently announced initial public offering ("IPO"), Steven Harris and Charles Swingland have respectively each transferred a proportion of their Ordinary Shares of 0.08p each into family trusts.

All of the Ordinary Shares held by the Directors and their family trusts are subject to a 12-month lock-up period from 13 March 2014 in relation to the IPO.

			Total interest, including shares held in family trusts
Director / PDMR	Title	Number of Ordinary Shares transferred on 17 March 2014	Number of Ordinary Shares	% of total issued share capital
Steven Harris	Chief Executive Officer	1,993,548	5,423,677	2.89%
Charles Swingland	Non-Executive Director	1,993,548	5,186,302	2.77%

The Company has 187,422,379 Ordinary Shares in issue, each with equal voting rights.  This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company.

-Ends-

For further information, please contact:
Circassia Pharmaceuticals plc Julien Cotta, Company Secretary	[phone]

 

END

 

 

RDSBLGDXUXBBGSI